Evidence map›Paper›PMID 40458573›Full record

ArticleAsian journal of urology2025

Single bladder instillation of gemcitabine versus mitomycin C after minimally invasive radical nephroureterectomy: A propensity-score match analysis from the ROBUUST 2.0 collaborative group.

Eugenio Bologna, Zhenjie Wu, Antonio Franco, Firas Abdollah, Marco Finati, Giuseppe Simone, Gabriele Tuderti, Leslie Claire Licari, Andres F Correa, Randall Lee and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Eugenio BolognaDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Zhenjie WuDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Antonio FrancoDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Firas AbdollahVattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
Marco FinatiVattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
Giuseppe SimoneDepartment of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Gabriele TudertiDepartment of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Leslie Claire LicariDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.
Andres F CorreaFox Chase-Temple Urologic Institute, Philadelphia, PA, USA.
Randall LeeFox Chase-Temple Urologic Institute, Philadelphia, PA, USA.
Ottavio De CobelliDivision of Urology, European Institute of Oncology-IRCCS, Milan, Italy.
Matteo FerroDivision of Urology, European Institute of Oncology-IRCCS, Milan, Italy.
Francesco PorpigliaDivision of Urology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy.
Daniele AmparoreDivision of Urology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy.
Enrico CheccucciDepartment of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Antonio TufanoIstituto Nazionale Tumori di Napoli, IRCCS Fondazione G. Pascale, Naples, Italy.
Sisto PerdonàIstituto Nazionale Tumori di Napoli, IRCCS Fondazione G. Pascale, Naples, Italy.
Raj BhanvadiaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Stephan BrönimannBrady Urological Institute, School of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
Nirmish SinglaBrady Urological Institute, School of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
Dhruv PuriDepartment of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
Ithaar H DerweeshDepartment of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
Dinno F MendiolaDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Mark L GonzalgoDesai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Reuben Ben-DavidDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Reza MehrazinDepartment of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sol C MoonDepartment of Urology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA.
Soroush Rais-BahramiDepartment of Urology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA.
Courtney YongDepartment of Urology, Indiana University, Indianapolis, IN, USA.
Chandru P SundaramDepartment of Urology, Indiana University, Indianapolis, IN, USA.
Alireza GhoreifiNorris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Farshad S MoghaddamNorris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Hooman DjaladatNorris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
Francesco DitonnoDepartment of Urology, University of Verona, Verona, Italy.
Alessandro AntonelliDepartment of Urology, University of Verona, Verona, Italy.
Riccardo AutorinoDepartment of Urology, Rush University Medical Center, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Radical nephroureterectomy (RNU) is considered the standard of care for patients with high-risk upper tract urothelial carcinoma. Current literature reveals a deficit in direct comparative studies evaluating the efficacy of different chemotherapeutic agents administered in single postoperative instillation following RNU. The primary aim of this study was to compare the bladder recurrence (BR) rates between patients receiving a single instillation of mitomycin C (MMC) versus gemcitabine (Gem) after RNU. Methods: The ROBUUST (ROBotic surgery for Upper tract Urothelial cancer STudy) 2.0 is an international, multicenter registry that aggregates data on patients who have undergone curative surgery for upper tract urothelial carcinoma across participating centers from January 2015 to December 2022. Data including primary baseline variables of the patients, characteristics of the tumors, surgical management, and definitive histopathological characterizations were collected and stratified based on the type of postoperative bladder instillation: MMC (the MMC group) and Gem (the Gem group). We selected variables correlated with our primary outcome to conduct a propensity-score match analysis. Results: One hundred patients in the MMC group were matched 1:1 with 100 patients in the Gem group. At 36 months of follow-up, 30 patients in the MMC group and 39 patients in the Gem group experienced BR, representing recurrence rates of 30% and 39%, respectively ( Conclusion: A single perioperative instillation of Gem or MMC seems to offer similar efficacy in reducing the risk of BR in patients undergoing RNU. Further research, ideally within the framework of prospective studies, is warranted to elucidate the optimal chemotherapeutic approach in this setting.

Indexed as

Adjuvant therapyBladder instillationGemcitabineMitomycin CUpper tract urothelial cancer

Identifiers

PMID40458573
PMCPMC12126943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.